One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

Published Date: 13 Dec 2024

Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

2.

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

3.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

4.

New imaging guidelines for head and neck cancers, a step toward practice change

5.

Even a few mutated cells can significantly impact how blood cancers develop, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot